Derek Archila, an analyst from Wells Fargo, maintained the Buy rating on Exelixis (EXEL – Research Report). The associated price target remains the same with $32.00. Derek Archila has given his Buy ...
Exelixis EXEL announced encouraging results from an expansion cohort of the early to mid-stage study of its next-generation oral TKI, zanzalintinib, in combination with either Bristol Myers' BMY ...
Shares of Exelixis, Inc. EXEL gained 7.4% on June 23, after the company announced positive top-line results from the late-stage STELLAR-303 study. This phase III study is a global, multicenter, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback